Medtronic is trading 4.1% down at $80.18 amid ongoing fallout from its cautious FY26 outlook and recent EPS guidance cuts linked to the MiniMed diabetes unit spin-off.
- Several analysts have reduced price targets over the past month following the company's updated financial projections and spin-off related adjustments.
- Broader healthcare sector weakness, driven by profit outlook concerns at major hospital operators, is adding further selling pressure to medical device names.